Biden Drug Price Report Takeaways

The Nephron Health Policy Team is out this afternoon with initial thoughts for subscribers on the released “Comprehensive Plan for Addressing High Drug Prices” report from the Biden administration.

The team discussed timing of the report in front of the expected $3.5 trillion 10-year spending and tax bill but ultimately re-focused investors on more important indicators like the Senate’s action on drug prices and what the report says about Medicare drug reimbursement via regulation and pilot projects WITHOUT Congress.

Paul and Sasha noted that the report DOES discuss mechanisms for the government to break market exclusivity protections for brand-name drugs without recommending specific action to do so, leaving it open as a possibility – a 30% risk, in our view.

For the full report and additional information on Nephron’s Health Policy product,